

E\_VS\_EFFECTOR\_CD8\_TCELL\_UP, GSE41867\_NAIVE\_VS\_EFFECTOR\_CD8\_TCELL\_UP

- GSE41867\_NAIVE\_VS\_DAY15\_LCMV\_EFFECTOR\_CD8\_TCELL\_UP, GSE41867\_NAIVE\_VS\_DAY15\_LCMV\_EFFECTOR\_CD8\_TCELL\_UP
- GSE41867\_DAY8\_EFFECTOR\_VS\_DAY30\_EXHAUSTED\_CD8\_TCELL\_LCMV\_CLONE13\_UP, GSE41867\_DAY8\_EFFECTOR\_VS\_DAY30\_EXHAUSTED\_CD8\_TCELL\_LCMV\_CLONE13\_UP
- GSE36078\_WT\_VS\_IL1R\_KO\_LUNG\_DC\_AFTER\_AD5\_T425A\_HEXON\_INF\_UP, GSE36078\_WT\_VS\_IL1R\_KO\_LUNG\_DC\_AFTER\_AD5\_T425A\_HEXON\_INF\_UP
- GSE5503\_MLN\_DC\_VS\_SPLEEN\_DC\_ACTIVATED\_ALLOGENIC\_TCELL\_DN, GSE5503\_MLN\_DC\_VS\_SPLEEN\_DC\_ACTIVATED\_ALLOGENIC\_TCELL\_DN
- GSE3982\_NEUTROPHIL\_VS\_CENT\_MEMORY\_CD4\_TCELL\_DN, GSE3982\_NEUTROPHIL\_VS\_CENT\_MEMORY\_CD4\_TCELL\_DN
- GSE17721\_LPS\_VS\_PAM3CSK4\_1H\_BMDC\_UP, GSE17721\_LPS\_VS\_PAM3CSK4\_1H\_BMDC\_UP
- GSE14308\_TH1\_VS\_NATURAL\_TREG\_UP, GSE14308\_TH1\_VS\_NATURAL\_TREG\_UP
- WHITFIELD\_CELL\_CYCLE\_M\_G1, WHITFIELD\_CELL\_CYCLE\_M\_G1
- GSE11961\_MARGINAL\_ZONE\_BCELL\_VS\_PLASMA\_CELL\_DAY7\_DN, GSE11961\_MARGINAL\_ZONE\_BCELL\_VS\_PLASMA\_CELL\_DAY7\_DN
- GOCC\_MICROBODY, GOCC\_MICROBODY
- MARTORIATI\_MDM4\_TARGETS\_NEUROEPITHELIUM\_UP, MARTORIATI\_MDM4\_TARGETS\_NEUROEPITHELIUM\_UP
- GSE4984\_UNTREATED\_VS\_VEHICLE\_CTRL\_TREATED\_DC\_DN, GSE4984\_UNTREATED\_VS\_VEHICLE\_CTRL\_TREATED\_DC\_DN
- BYSTRYKH\_HEMATOPOIESIS\_STEM\_CELL\_QTL\_CIS, BYSTRYKH\_HEMATOPOIESIS\_STEM\_CELL\_QTL\_CIS
- GSE5542\_IFNA\_VS\_IFNA\_AND\_IFNG\_TREATED\_EPITHELIAL\_CELLS\_24H\_UP, GSE5542\_IFNA\_VS\_IFNA\_AND\_IFNG\_TREATED\_EPITHELIAL\_CELLS\_24H\_UP
- ICHIBA\_GRAFT\_VERSUS\_HOST\_DISEASE\_D7\_UP, ICHIBA\_GRAFT\_VERSUS\_HOST\_DISEASE\_D7\_UP
- GSE7852\_TREG\_VS\_TCONV\_THYMUS\_UP, GSE7852\_TREG\_VS\_TCONV\_THYMUS\_UP
- GSE2585\_CTEC\_VS\_THYMIC\_DC\_DN, GSE2585\_CTEC\_VS\_THYMIC\_DC\_DN
- HOSHIDA\_LIVER\_CANCER\_SURVIVAL\_DN, HOSHIDA\_LIVER\_CANCER\_SURVIVAL\_DN
- MIR2053, MIR2053
- HP\_ABNORMAL\_ENCHONDRAL\_OSSIFICATION, HP\_ABNORMAL\_ENCHONDRAL\_OSSIFICATION
- WP\_GLYCEROPHOSPHOLIPID\_BIOSYNTHETIC\_PATHWAY, WP\_GLYCEROPHOSPHOLIPID\_BIOSYNTHETIC\_PATHWAY
- GSE1791\_CTRL\_VS\_NEUROMEDINU\_IN\_T\_CELL\_LINE\_12H\_DN, GSE1791\_CTRL\_VS\_NEUROMEDINU\_IN\_T\_CELL\_LINE\_12H\_DN
- HP\_UPPER\_LIMB\_SPASTICITY, HP\_UPPER\_LIMB\_SPASTICITY
- HP\_NECK\_MUSCLE\_WEAKNESS, HP\_NECK\_MUSCLE\_WEAKNESS
- CHANGOLKAR\_H2AFY\_TARGETS\_UP, CHANGOLKAR\_H2AFY\_TARGETS\_UP
- GOBP\_POSITIVE\_REGULATION\_OF\_PEPTIDE\_HORMONE\_SECRETION, GOBP\_POSITIVE\_REGULATION\_OF\_PEPTIDE\_HORMONE\_SECRETION
- MIR3137, MIR3137
- GOBP\_POSITIVE\_REGULATION\_BY\_HOST\_OF\_VIRAL\_TRANSCRIPTION, GOBP\_POSITIVE\_REGULATION\_BY\_HOST\_OF\_VIRAL\_TRANSCRIPTION
- HP\_BRUSHFIELD\_SPOTS, HP\_BRUSHFIELD\_SPOTS
- GTCAACC\_MIR3805P, GTCAACC\_MIR3805P
- REACTOME\_CDC6\_ASSOCIATION\_WITH\_THE\_ORC\_ORIGIN\_COMPLEX, REACTOME\_CDC6\_ASSOCIATION\_WITH\_THE\_ORC\_ORIGIN\_COMPLEX
- HP\_ABNORMALITY\_OF\_UPPER\_LIMB\_EPIPHYSIS\_MORPHOLOGY, HP\_ABNORMALITY\_OF\_UPPER\_LIMB\_EPIPHYSIS\_MORPHOLOGY
- HP\_DEVIATION\_OF\_THE\_5TH\_TOE, HP\_DEVIATION\_OF\_THE\_5TH\_TOE
- HP\_HYPERCONVEX\_NAIL, HP\_HYPERCONVEX\_NAIL
- GNCF\_01, GNCF\_01
- CAO\_BLOOD\_FLUZONE\_AGE\_05\_14YO\_CORRELATED\_WITH\_H3N1\_HI\_TITER\_1DY\_POSITIVE, CAO\_BLOOD\_FLUZONE\_AGE\_05\_14YO\_CORRELATED\_WITH\_H3N1\_HI\_TITER\_1DY\_POSITIVE
- HP\_POSTERIOR\_FOSSA\_CYST, HP\_POSTERIOR\_FOSSA\_CYST
- GOMF\_GLYCEROPHOSPHOLIPID\_FLIPPASE\_ACTIVITY, GOMF\_GLYCEROPHOSPHOLIPID\_FLIPPASE\_ACTIVITY
- DESCARTES\_MAIN\_FETAL\_BRONCHIOLAR\_AND\_ALVEOLAR\_EPITHELIAL\_CELLS, DESCARTES\_MAIN\_FETAL\_BRONCHIOLAR\_AND\_ALVEOLAR\_EPITHELIAL\_CELLS
- HP\_ADRENAL\_HYPOPLASIA, HP\_ADRENAL\_HYPOPLASIA
- HP\_INSPIRATORY\_STRIDOR, HP\_INSPIRATORY\_STRIDOR
- HP\_LATE\_ONSET\_PROXIMAL\_MUSCLE\_WEAKNESS, HP\_LATE\_ONSET\_PROXIMAL\_MUSCLE\_WEAKNESS